The Pentafill L + Fill is a new bench-top vial filling and sealing machine for lab research and small quantity start-up production.
Tekni-Plex launched the Pentafill L + Fill, a new bench-top vial filling and sealing machine for lab research and small quantity start-up production.
With the ability to accommodate five-unit strips of 0.33-mL, 0.6-mL, 1-mL, 3-mL, 5-mL, and 10-ml plastic vials, the machine executes a fill or seal after an operator loads the five-unit strips into a holder, which is then manually inserted into the machine. The vials are then filled and sealed automatically, followed by manual removal of the holder.
The machine comes equipped with a heating head, cold-molding pliers, a sealer, interchangeable holders for different vial capacities, and external controls to perform the fill and seal.
“Up until now, pharmaceutical companies and labs had to manually fill small-scale production vials before inserting them into the machine for sealing. This resulted in fills that were frequently imprecise and therefore not ideal for lab research or therapeutic use. To help eliminate that issue, our customers asked us to create a unit that would provide precision fills, each and every time,” said Melissa Green, global senior director marketing and strategy, Tekni-Plex Healthcare Packaging, in a July 22, 2020 company press release.
“The demand for this type of capability continues to increase as pharmaceutical manufacturers look for alternatives to expensive, hard-to-source glass vials,” Green added, in the press release. “Additionally, new unit dose applications continue to be developed making the Pentafill L + Fill an ideal unit for lab studies and small-scale production.”
Source: Tekni-Plex
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.